Iovance Stock Been Hammered: A Buying Opportunity or Lure for Risky Bets
Iovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
Learn when mutual funds can be preferable to index funds, considering objectives, risk tolerance, and horizon. Make informed allocation decisions.
25,127 articlesIovance Biotherapeutics has shown dramatic swings, with recent gains masking a long history of volatility. This piece...
PowerFleet is reshaping fleet management with AI-powered IoT. This guide breaks down what to expect from powerfleet (...
Venice AI closes a $65 million Series A led by Dragonfly at a $1 billion valuation, funding growth with equity. The m...
Vertex is pursuing Crinetics with a substantial all-cash offer. This deep dive breaks down what the $10 billion bid m...
The Digital Chamber filed a lawsuit against Illinois over a 0.2% tax on digital asset transactions, arguing the levy ...
Kratos Defense stock just surged after two new contract wins. This article breaks down what happened, why it matters,...
If you’re evaluating FLR, you’re weighing big projects, complex contracts, and a shifting risk profile. This guide br...
I dove into Plug Power in a hopeful stretch for green energy gains, only to see a dramatic crash. This is the hard-wo...
A wave of previously inaccessible BTC could re-enter markets in March, testing a fragile price zone and highlighting ...
As Medicare costs rise with MAGI, retirees are turning to a tax-efficient move: roll assets from a traditional 401K t...
Investors study the math behind replacing a $75,000 salary with monthly dividend ETFs, weighing yield, risk, and long...
As Hillman prepares to share Q1 2026 results, investors want clarity on growth, margins, and cash flow. This practica...